Clinical trial
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With…
NCT00309985 · ECOG-ACRIN Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00309985 |
|---|---|
| Title | Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer |
| Official title | CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer |
| Acronym | CHAARTED |
| Lead sponsor | ECOG-ACRIN Cancer Research Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Hormone-sensitive Prostate Cancer |
| Intervention type | Drug |
| Interventions | androgen-deprivation therapy, docetaxel |
| Enrollment | 790 |
| Start date | Sep 26, 2006 |
| Primary completion | Dec 23, 2013 |
| Completion | Jan 31, 2025 |
| First posted | Apr 3, 2006 |
| Last update posted | Dec 11, 2025 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: